Project description
RNA technology for rapid development of vaccines against emerging viruses
Recent events of viral epidemics and epizootics demonstrated that conventional vaccine development requires too much time. Dutch company BunyaVax is developing novel technology for the cost-effective and rapid production of vaccines against emerging viruses. The company's proprietary RNA particle technology is a plug-and-play application combining safety with strong efficacy. Viral genes can be introduced into the RNA particle genome to generate a range of new potent vaccines. An important advantage is that development and production can be completed within 16 weeks, which is twice as fast as current methods. The EU-funded RAPID project aims to demonstrate the feasibility of medium- to large-scale vaccine production, prove its efficacy in sheep and develop a detailed business plan for BunyaVax.
Objective
BunyaVax builds unprecedented technology for cost-effective and rapid development of vaccines
against newly emerging viruses. The platform can be a valuable tool in quickly controlling the spread of new virus strains
among populations. The timing of RAPID closely corresponds with a current focus of the vaccine industry on novel vaccine
platform technologies that enable rapid response to emerging threats.
The BunyaVax RNA particle technology combines the efficacy of live vaccines with the safety of inactivated or subunit
vaccines – which are currently the standard vaccine technologies. A unique characteristic of the RNA platform is that it
allows for ‘plug and play’ application. Any gene can be plugged into the RNA particle genome to generate inherently safe
and efficacious vaccines. The platform can stably express a broad variety of pathogen derived antigens. A major advantage
is that development and manufacturing can be completed in a timeframe of 16 weeks which is at least twice as fast as
current methods. The BunyaVax technology is in a stage of proven efficacy in sheep.
RAPID is designed to prepare for partnerships with vaccine manufacturers and/or venture capital firms and to lay the
foundation for clinical application of the vaccine platform. Key steps for upscaled production levels will be taken.
The innovation project is at the core of the strategy of BunyaVax. The project is instrumental for reaching a stage in which commercial partnerships can be explored. Ultimately, this will allow BunyaVax to forward the technology to a stage in which industry can use it to develop vaccines for controlling veterinary and human infectious disease outbreaks at an earlier stage than currently possible.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences infectious diseases RNA viruses ebola
- medical and health sciences health sciences infectious diseases RNA viruses influenza
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- natural sciences biological sciences genetics RNA
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
8221 RA LELYSTAD
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.